Kallikrein gene expression in estrogen-induced pituitary tumors

Peter J. Fuller, Bronwyn A. Matheson, Raymond J. MacDonald, Karen Verity, Judith A. Clements

Research output: Contribution to journalArticlepeer-review

21 Scopus citations


Anterior pituitary kallkrein-like enzyme activity, immunoreactivity and mRNA levels have previously been shown to be regulated by estrogen, in parallel with prolactin. In this study, we have examined the relationship between kallikrein and prolactin mRNA levels in estrogen-induced pituitary tumors. Treatment of Fischer 344 rats with diethylstilbestrol implants for 3, 5 and 7 weeks produced a dramatic increase in kallikrein mRNA levels and a modest increase in prolactin mRNA levels. These changes were partially reversed by bromocriptine treatment, and completely reversed by bromocriptine plus estrogen withdrawal. Using a panel of oligonucleotide probes specific for various members of the rat kallikrein gene family, we have shown that the kallikrein-like gene expressed appears to be true kallikrein.

Original languageEnglish (US)
Pages (from-to)225-232
Number of pages8
JournalMolecular and Cellular Endocrinology
Issue number2-3
StatePublished - Dec 1988


  • Anterior pituitary
  • Bromocriptine
  • Kallikrein
  • Prolactin
  • Prolactinoma

ASJC Scopus subject areas

  • Biochemistry
  • Molecular Biology
  • Endocrinology


Dive into the research topics of 'Kallikrein gene expression in estrogen-induced pituitary tumors'. Together they form a unique fingerprint.

Cite this